One hundred patients [CKD Stages 3.5, Hb. 110 g/L, iron replete, erythropoietin-stimulating agent (ESA)-naive, 47 diabetic, median age 69.5 years] were block-randomized in an open-label study to receive up to 200 mg intravenous iron sucrose (Group A, n=52) bimonthly or oral iron sulphate (Group B) to maintain raised and normal iron indices (respectively) over 12 months. The primary endpoint was the change in Hb concentration at 12 months or at termination after at least 6 months of treatment.
McMahon, L. P., Kent, A. B., Kerr, P. G., Healy, H., Irish, A. B., Cooper, B., Kark, A., & Roger, S. D. (2010). Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: A randomized controlled trial. Nephrology Dialysis Transplantation, 25(3), 920 - 926. https://doi.org/10.1093/ndt/gfp584